Agilent Technologies reports that it acquired 20 acres in Weld County in northern Colorado, on which it plans to build a pharmaceutical manufacturing facility.

“The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases,” said Skip Thune, general manager of the company’s nucleic acids solutions division. “We are committed to meeting the ever-increasing needs of our customers for oligonucleotides.”

Researchers believe oligonucleotides hold the potential to treat various forms of cancer, diabetes, muscular dystrophy, and other disorders, according to Thune, who noted that the expansion would result in about 150 to 200 new jobs.

Previous articleBMS Reacquires Asian Rights to Aslan’s Solid-Tumor Candidate
Next articleMalaria Transmission Significantly Reduced Using Human Odor-Baited Traps